Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen
27 oct. 2023 11h00 HE
|
Psychemedics Corporation
Psychemedics debuts a 5-panel drug test replacing marijuana with fentanyl, the first hair drug test exclusively targeting the most dire workplace threats.
Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer
21 sept. 2023 17h00 HE
|
Psychemedics Corporation
ACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon...
Psychemedics Corporation Announces New Brazilian Distribution Agreement
19 sept. 2019 17h25 HE
|
Psychemedics Corporation
ACTON, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) announced today that it has entered into a new distribution agreement in Brazil with Sansão Holding S.A. and...
Psychemedics Announces Second Quarter Results and Declares 92nd Consecutive Quarterly Dividend
23 juil. 2019 17h25 HE
|
Psychemedics Corporation
ACTON, Mass., July 23, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2019. The Company also announced...
ALERT: Rosen Law Firm Reminds Psychemedics Corporation Investors of Important Deadline in Class Action – PMD
13 mars 2017 17h53 HE
|
The Rosen Law Firm PA
NEW YORK, March 13, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Psychemedics Corporation securities (NASDAQ:PMD) from February 28, 2014 through...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Psychemedics Corporation – PMD
27 févr. 2017 18h05 HE
|
The Rosen Law Firm PA
NEW YORK, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Psychemedics Corporation...